Skip to content

Sinopharm Explores $1 Billion Deal for BBI Life Sciences

  • State-owned pharma giant is among potential buyers for BBI
  • BBI Life went public in 2014; taken private six years later

China National Pharmaceutical Group Co. is among suitors exploring a potential acquisition of BBI Life Sciences Corp., in a deal that could value the Shanghai-based DNA synthesis products supplier at more than $1 billion, according to people familiar with the matter.

The state-owned company, known as Sinopharm, has held talks with BBI Life’s founding Wang family about a transaction, said the people, who asked not to be identified as the information is private. BBI Life’s owner is also in discussions with other possible buyers, the people said.